Education
About Us
Working with TipRanks
Follow Us
CERo Therapeutics Holdings (CERO)
NASDAQ:CERO
RESEARCH TOOLSreports
Total Valuation
CERo Therapeutics Holdings has a market cap or net worth of $5.51M. The enterprise value is -$327.27K.
Market Cap$5.51M
Enterprise Value-$327.27K
Share Statistics
CERo Therapeutics Holdings has 516,092 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding516,092
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
CERo Therapeutics Holdings’s return on equity (ROE) is 5.85 and return on invested capital (ROIC) is 5076.72%.
Return on Equity (ROE)5.85
Return on Assets (ROA)-1.79
Return on Invested Capital (ROIC)5076.72%
Return on Capital Employed (ROCE)13.55
Revenue Per Employee0.00
Profits Per Employee-911.20K
Employee Count8
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of CERo Therapeutics Holdings is -1.31. CERo Therapeutics Holdings’s PEG ratio is <0.01.
PE Ratio-1.31
PS Ratio0.00
PB Ratio-4.73
Price to Fair Value-7.65
Price to FCF-0.68
Price to Operating Cash Flow-0.30
PEG Ratio<0.01
Income Statement
In the last 12 months, CERo Therapeutics Holdings had revenue of 0.00 and earned -7.73M in profits. Earnings per share was -18.15.
Revenue0.00
Gross Profit0.00
Operating Income-15.30M
Pretax Income-7.73M
Net Income-7.73M
EBITDA-6.57M
Earnings Per Share (EPS)-18.15
Cash Flow
In the last 12 months, operating cash flow was -5.16M and capital expenditures -4.00, giving a free cash flow of -5.16M billion.
Operating Cash Flow-5.16M
Free Cash Flow-5.16M
Free Cash Flow per Share-9.99
Dividends & Yields
CERo Therapeutics Holdings pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-0.76
52-Week Price Change-98.48%
50-Day Moving Average12.54
200-Day Moving Average109.55
Relative Strength Index (RSI)49.62
Average Volume (3m)2.10M
Important Dates
CERo Therapeutics Holdings upcoming earnings date is ―, TBA Not Confirmed.
Last Earnings Date―
Next Earnings Date―
Ex-Dividend Date―
Financial Position
CERo Therapeutics Holdings as a current ratio of 0.50, with Debt / Equity ratio of -414.89%
Current Ratio0.50
Quick Ratio0.50
Debt to Market Cap0.06
Net Debt to EBITDA0.25
Interest Coverage Ratio0.00
Taxes
In the past 12 months, CERo Therapeutics Holdings has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
CERo Therapeutics Holdings EV to EBITDA ratio is -1.78, with an EV/FCF ratio of -2.20.
EV to Sales0.00
EV to EBITDA-1.78
EV to Free Cash Flow-2.20
EV to Operating Cash Flow-2.20
Balance Sheet
CERo Therapeutics Holdings has $5.20M in cash and marketable securities with $1.37M in debt, giving a net cash position of -$3.84M billion.
Cash & Marketable Securities$5.20M
Total Debt$1.37M
Net Cash-$3.84M
Net Cash Per Share-$7.43
Tangible Book Value Per Share-$0.78
Margins
Gross margin is 24.78%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin24.78%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for CERo Therapeutics Holdings is $3.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$3.00
Price Target Upside-71.91% Downside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast―
EPS Growth Forecast―